

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	NeuroScientific Biopharmaceuticals Limited
ABN	13 102 832 995

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Brian Leedman
Date of last notice	23 November 2018

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct and Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	As director and shareholder of Tashtech Pty Ltd
Date of change	06 December 2018
No. of securities held prior to change	<u>Direct:</u> 1,838,130 Ordinary shares (1,450,000 escrowed until 27 July 2020) 250,000 Class B Performance Shares 250,000 Class C Performance Shares 250,000 Class D Performance Shares 250,000 Class E Performance Shares <u>Indirect:</u> 91,875 Ordinary shares
Class	Unlisted Options

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Number acquired	Direct : 700,000 Indirect: nil
Number disposed	Direct: n/a Indirect: n/a
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	Direct: \$7,000 Indirect: \$nil
No. of securities held after change	<u>Direct:</u> 1,838,130 Ordinary shares (1,450,000 escrowed until 27 July 2020) 250,000 Class B Performance Shares 250,000 Class C Performance Shares 250,000 Class D Performance Shares 250,000 Class E Performance Shares 700,000 Unlisted options (exercisable at \$0.20 on or before 7 March 2021) <u>Indirect:</u> 91,875 Ordinary shares
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Acceptance of non-renounceable entitlement issue

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	-
Nature of interest	-
Name of registered holder (if issued securities)	-
Date of change	-

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	-
Interest acquired	-
Interest disposed	-
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	-
Interest after change	-

Part 3 – ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	n/a
If prior written clearance was provided, on what date was this provided?	n/a

⁺ See chapter 19 for defined terms.